Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedinotecMDNC 24 Return-on-Tangible-Asset is 12.87% as of May. 2026, which is 770% above its 10-year median of 1.48. GuruFocus rates MDNC with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Medinotec's annualizedNet Income for the quarter that ended in May. 2026 was $0.89 Mil. Medinotec's average total tangible assets for the quarter that ended in May. 2026 was $6.90 Mil. Therefore, Medinotec's annualized Return-on-Tangible-Asset for the quarter that ended in May. 2026 was 12.87%.
The historical rank and industry rank for Medinotec's Return-on-Tangible-Asset or its related term are showing as below:
MDNC'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -12.15 Med: 1.48 Max: 37.18
Current: 13.11
During the past 5 years, Medinotec's highest Return-on-Tangible-Asset was 37.18%. The lowest was -12.15%. And the median was 1.48%.
MDNC's Return-on-Tangible-Asset is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.62
vs MDNC: 13.11
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Medinotec Return-on-Tangible-Asset Related Terms
Medinotec Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Medinotec's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDNC vs NVNO, APYX, RDGL: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Medinotec's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinotec Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medinotec's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Medinotec's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (May. 2026) net income data.
What does a Return-on-Tangible-Asset of 12.87% mean?
Medinotec (MDNC) has a Return-on-Tangible-Asset of 12.87% as of May. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Medinotec and its competitors. This is 770% above median its historical median of 1.48.
Is Medinotec's Return-on-Tangible-Asset too high?
Medinotec's current Return-on-Tangible-Asset of 12.87% is 770% above median its 10-year median of 1.48. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.62. Medinotec's value of 12.87% is 1975.8% above this industry median. Overall, Medinotec has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Medinotec's Return-on-Tangible-Asset compare to NVNO and APYX?
Medinotec's Return-on-Tangible-Asset of 12.87% can be compared against companies in the Medical Devices & Instruments industry. The industry median Return-on-Tangible-Asset is 0.62. Medinotec's value of 12.87% is 1975.8% above this benchmark. While the company's 10-year median is 1.48 vs. the industry median of 0.62, Medinotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.62, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinotec's current Return-on-Tangible-Asset of 12.87% is 1975.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Medinotec and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinotec's current Return-on-Tangible-Asset is 12.87%, which is 770% above median its own 10-year median of 1.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinotec stock overvalued right now?
Medinotec (MDNC) has a current Return-on-Tangible-Asset of 12.87%. The current Return-on-Tangible-Asset is 12.87%, which is 770% above median its 10-year median of 1.48 and 1975.8% above the Medical Devices & Instruments industry median of 0.62. Medinotec's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Medinotec (MDNC), the current Return-on-Tangible-Asset is 12.87% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medinotec Inc is a medical device manufacturing and distribution company engaged in tracheal non-occlusive airway dilation technology and medical device design. It generates revenue from two sources: internally designed and manufactured medical devices and distribution of third-party medical products under exclusive or non-exclusive agreements in defined territories. Its products include the Trachealator, the Outflo Aortic Valve Dilation Balloon Catheter, and the Cape Cross family of PTCA balloon catheters. It also distributes a range of cardiology and renal dialysis products on behalf of multinational manufacturers, mainly in South Africa. Its segments are Inside the United States and Outside the United States, with Outside the United States generating maximum revenue.
24GF Score
Get the complete analysis for MDNC
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDNC has been successfully added to your 
